Effect of Rituximab in Treatment of Membranoproliferative Glomerulonephritis
Status:
Unknown status
Trial end date:
2019-12-01
Target enrollment:
Participant gender:
Summary
Type I membranoproliferative glomerulonephritis (MPGN) is a relatively uncommon glomerular
disease, constituting 1.8% of renal biopsies performed in Rochester, minnesota, United States
of America, at the Mayo Clinic, between 1993 and 2008. The prognosis of idiopathic Type I
MPGN is relatively poor. Recently, Irish series, slightly more than 50% of patients developed
end stage renal disease after a mean follow up of 14 years . The disease may recur after
renal transplantation . High-dose glucocorticoids have been used to treat this disease in
children but there is no established treatment in adults.